DOCSLIB.ORG

USP MEDICARE MODEL GUIDELINES V6.0

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
USP MEDICARE MODEL GUIDELINES V6.0 FINAL REPORT, SUMMARY OF METHODOLOGY AND APPROACH USP MEDICARE MODEL GUIDELINES v6.0 COOPERATIVE AGREEMENT USP Medicare Model Guidelines Version 6.0 Award Authority: Congressional Earmark, Section 1860-D-4(b)(C)(ii) of the Medicare Prescription Drug Improvement and Modernization Act of 2003 Grant Number: 1C0CMS331232-01-00 Project/Program Title: USP 2013 Federal Project Officer: LT. Marie Manteuffel CMS Grants Management Specialist: Linda Gmeiner USP Principal Investigator: Angela G. Long, M.S. Project Director: Jami S. Earnest, Pharm.D. Submitted by the United States Pharmacopeial Convention February 3, 2014 (Revised April 15, 2014) The statements contained in this report are solely those of the authors and do not necessarily reflect the views or policies of the Centers for Medicare & Medicaid Services (CMS). The grantee assumes responsibility for the accuracy and completeness of the information in this report. CMS only funds the development of Categories and Classes and not additional material. TABLE OF CONTENTS INTRODUCTION ............................................................................................................. 4 METHODOLOGY AND APPROACH .............................................................................. 5 Update Categories and Classes ................................................................................................................ 5 Summary. .................................................................................................................................................. 5 Interactions Between USP and CMS ........................................................................................................ 6 Start-up Meeting .................................................................................................................................... 6 CMS Attendance at Expert Committee Meetings. ................................................................................ 6 USP-CMS Staff Meetings. ..................................................................................................................... 7 Submission of Written Materials............................................................................................................ 7 Therapeutic Information and Formulary Support Expert Committee (TIFS EC) ....................................... 7 Reporting of Conflict of Interest............................................................................................................. 8 Deliberation of the Expert Committee ................................................................................................... 8 Balloting of the TIFS Expert Committee ................................................................................................ 8 Guiding Principles of Model Guidelines Expert Committee ...................................................................... 9 Identification of New Part D Drugs and New Therapeutic Uses ............................................................... 9 Review of FDA actions. ......................................................................................................................... 9 Comparison of CMS Formulary Reference File and USP Medicare Model Guidelines v5.0 .............. 10 Review of New Medicare Legislation. ................................................................................................. 10 Development of Drug Information Resources to Support Expert Committee Deliberation ..................... 10 Drug Summary Files. .......................................................................................................................... 10 USP Management and Personnel .......................................................................................................... 11 USP Staff ............................................................................................................................................. 11 Drug Information Support. ................................................................................................................... 11 Address Issues .......................................................................................................................................... 11 Public Comment Mechanisms................................................................................................................. 11 Stakeholder 1:1 Consultations ............................................................................................................ 12 Open Microphone Web Meetings........................................................................................................ 12 Public Comments ................................................................................................................................ 12 CMS Comments ...................................................................................................................................... 12 TIFS Expert Committee Deliberation on Public Comments .................................................................... 12 Comments Directed to CMS from External Parties ................................................................................ 13 Comments Directed to CMS from USP ................................................................................................... 13 Comments from USP: Interagency Communication and Stakeholder Input ........................................... 14 SUMMARY OF REVISIONS, USP MEDICARE MODEL GUIDELINES V6.0 ............... 14 USP Categories and Classes ................................................................................................................... 14 Stability of USP Categories and Classes ................................................................................................ 14 Revision Summary .................................................................................................................................. 15 Revised USP Categories ........................................................................................................................ 16 Removed USP Category/ USP Class: Hormonal Agents, Suppressant (Sex Hormones/ Modifiers), Antiandrogens ..................................................................................................................................... 16 Renamed USP Category: Respiratory Tract/ Pulmonary Agents ....................................................... 17 Revised USP Classes ............................................................................................................................. 17 Removed USP Class: Glucocorticoids/ Mineralocorticoids ................................................................ 17 New USP Class: Opioid Dependence Treatments and Renamed USP Class: Opioid Reversal Agents ............................................................................................................................................................ 17 New USP Class: Antineoplastics, Antiandrogens ............................................................................... 17 2 New USP Class: Anti-hepatitis C (HCV) Agents, and Renamed USP Class: Anti-hepatitis B (HBV) Agents ................................................................................................................................................. 18 New USP Class: Anti-HIV Agents, Integrase Inhibitors (INSTI) ......................................................... 18 New USP Class: Benzodiazepines ..................................................................................................... 18 New USP Class: Angioedema (HAE) Agents ..................................................................................... 18 New USP Class: Cystic Fibrosis Agents ............................................................................................. 19 Renamed USP Class: SSRIs/SNRIs (Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors) .................................................................................................. 19 Renamed USP Class Phosphodiesterase Inhibitors, Airways Disease .............................................. 19 Single-Drug USP Categories or Classes ................................................................................................ 19 Alignment of USP Medicare Model Guidelines with CMS Formulary Reference File ........................ 21 Erratum: Classification of Combination Product, Atripla (Efavirenz/ Emtricitabine/ Tenofovir disoproxil fumarate) .................................................................................................................................. 21 Appendix II: Excerpts from Rules and Procedures of the 2010-2015 USP Council of Experts ........ 23 Appendix III: Members of the USP Therapeutic Information and Formulary Support Expert Committee .................................................................................................................................................. 26 Appendix IV: Guiding Principles ............................................................................................................. 28 Appendix V: Drugs Reviewed by the TIFS EC........................................................................................ 30 Appendix VI: Stakeholder 1:1 Consultations ......................................................................................... 48 Appendix VII: Open Microphone Web Meetings ...................................................................................
Load more

Recommended publications
  • Glaxosmithkline Bangladesh Limited (GSK)
    GlaxoSmithKline Bangladesh Limited (GSK) Recruitment and Selection Process of GlaxoSmithKline Bangladesh Limited: An Evaluation nd Date of Submission: 2 September, 2014 ©Daffodil International University DAFFODIL INTERNATIONAL UNIVERSITY Internship Report On Recruitment and Selection Process of GlaxoSmithKline Bangladesh Limited: An Evaluation Submitted To Dr. Zakir Hossain Dean& Professor Faculty of Business & Economics Daffodil International University Submitted By Ishrat Jahan ID: 131-14-1019 Masters of Business Administration Daffodil International University Date of Submission: 2nd September, 2014 ©Daffodil International University Letter of Transmittal September 2, 2014 To Dr. Zakir Hossain Dean & Professor Faculty of Business and Economics Daffodil International University Dhaka-1205 Subject: Submission of internship report on recruitment and selection process: An evaluation of GlaxoSmithKline Bangladesh Limited Sir, I am highly satisfied to submit my report on recruitment and selection process: an evaluation of GSK. For preparing this report I tried my best to accumulate relevant and upgraded information from available sources. In preparing this report, I tried my level best to make it a complete one and sincerely look forward to any possible correction. I am very glad because you also given the opportunity to prepare this report .I hope that this report will meet the standards of your judgments. Your Sincerely ---------------- Ishrat Jahan ©Daffodil International University i Certificate of the Supervisor This is to certify that the internship report titled ―Recruitment and Selection Process of GlaxoSmithKline Bangladesh Limited: An Evaluation‖, has been prepared by Ms. Ishrat Jahan bearing ID: 131-14-1019 under my supervision, a practical study on GlaxoSmithKline Bangladesh Limited. I think on the basic of declaration Ms.
    [Show full text]
  • Annual Report 2013
    Annual Report 2013 “ Being active and having a positive outlook on life is what keeps me going every day.” Overview of 2013 “ Our performance in 2013 was defined by remarkable &R D output and further delivery of sustained financial performance for our shareholders.” Please go to page 4 for more More at gsk.com Performance highlights £26.5bn £8.0bn £7.0bn £5.2bn Group turnover Core* operating profit Total operating profit Returned to shareholders 6 112.2p 112.5p 13% Major medicines approved Core* earnings per share Total earnings per share Estimated return on R&D investment 10 6 1st 1st Potential phase III study starts in 2014/15 Potential medicines with phase III data in Access to Medicines Index Pharmaceutical company to sign AllTrials expected 2014/15 campaign for research transparency Front cover story Betty, aged 65, (pictured) has Chronic “ Health is important to me, Obstructive Pulmonary Disease (COPD). She only has 25% lung capacity. This means I try to take care of my she finds even everyday tasks difficult, but medicines and inhaled oxygen allow her to health with all the tools live as normal a life as she can. Betty’s mindset I have and do the best is to stay busy and active, so every week she goes to rehab exercise classes. that I can with it.” COPD is a disease of the lungs that leads to Betty, COPD patient, damaged airways, causing them to become North Carolina, USA narrower and making it harder for air to get in and out. 210 million people around the world are estimated to have COPD.
    [Show full text]
  • A Case Study of Glaxosmithkline Plc )
    )l GROWTH THROUGH MERGER: A CASE STUDY OF GLAXOSMITHKLINE PLC ) / BY JUNE WANGARI UNIVERSITY OF NAIR03J LOWER KABETE LIBRARY A MANAGEMENT RESEARCH PROJECT SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE AWARD OF DEGREE OF MASTER OF BUSINESS ADMINISTRATION (MBA), SCHOOL OF BUSINESS, UNIVERSITY OF NAIROBI JULY, 2008 DECLARATION I declare that this project is my original work and has never been presented for academic purposes in any other University. CANDIDATE: JUNE WANGARI DATE .(.91. This research project has been submitted for examination with my approval as the University Supervisor SIGNED. DATE. Prof. Evans Aosa Department Of Business Administration, School Of Business, University Of Nairobi 11 DEDICATION I dedicate this project to my daughter Jemima, who was born within the first year of my post graduate studies. And now that she is in kindergarten, I see that I have instilled in her the love for reading and learning and I trust that she will go very far. iii ACKNOWLEDGEMENT I thank God for seeing me through my studies as I tried to balance between my family, my work and my studies. I wish to acknowledge the contributions that were made in the course of this project by several individuals and organizations. I wish to acknowledge gratefully the following people, whose effort influenced the content and direction of this project. My first thanks go to my Supervisor Prof. Evans Aosa for his constant analytical criticism and encouragement. Thanks a lot. I wish to thank my friends for a lot of support and encouragement to me in pursuit of this goal.
    [Show full text]
  • Uzomis: at All Doses Compared to Those on Placebo
    persistent and recurrent headache. The frequency and time to use of these additional WARNINGS treatments were also recorded. ZOMIG* (zolmitriptan) should only be used where a clear diagnosis of migraine Table 1 shows efficacy results for ZOMIG" in 5 placebo-controlled trials, 4 of which were has been established. multicenter. The percentage of patients with pain relief (grade 1/0) at 2 hours after treatment Risk of Myocardial Ischemia ami/or Infarction and Other Adverse Cardiac Events: (the primary endpoint measure) was significantly greater among patients receiving ZOMIG* 2DWB* has beMassccMedwMtmis^ chest siMfrJMkpste and 8ghtoe& UZomis: at all doses compared to those on placebo. In Study 3, which directly compared the 1 mg, which may resemble angina pectoris. Following the use of other 5-HTj 2.5 mg and 5 mg doses, there was a statistically significant greater proportion of patients with agonists, In rare cases these symptoms have been Identified as being the likely zolmitriptan tablets 2.5 mg headache response at 2 and 4 hours in the higher dose groups (2.5 mg or 5 mg) than in the result of coronary vasospasm or myocardial Ischemia. Rare cases of serious 1 mg group. There was no statistically significant difference between the 2.5 mg and 5 mg PHARMACOLOGICAL CLASSIFICATION coronary events or arrhythmia have occurred following use ot S-HTt agonists, dose groups for the primary endpoint measure of pain relief (1/0) at 2 hours, or at any other including ZOMIG*. ZOMIG* should not be given to patients who have documented 5-HTi Receptor Agonist time point measured.
    [Show full text]
  • API Written Confirmation 02-08-2021
    MHRA Register of Written Confirmations For UK Active Substance Manufacturers The information published in this document was that held by the MHRA on the date of publication. Please note the site register will be updated on a Monthly basis. Date of Publication: 02/08/2021 Copyright © by the Department of Health and Social Care and MHRA, 10 South Colonnade, Canary Wharf, London E14 4PU T 020 3080 6000 – www.mhra.gov.uk NOTICES The Agency’s register is computerised. Every site and every Written Confirmation has a unique number that should be quoted when enquiries are made. NOTES FOR GUIDANCE GENERAL The Written Confirmations have been generated for UK Active Substance Manufacturing sites to support the export of Active Substances to the EEA. The Written Confirmation Number is a specific number allocated to each site. The Table of Contents contains a link to the relevant Written Confirmation for each company within this document. Table of Contents A NELSON AND COMPANY LIMITED AIR PRODUCTS PLC ALBUMEDIX LIMITED ALLIANCE MEDICAL RADIOPHARMACY LIMITED ALLIANCE MEDICAL RADIOPHARMACY LIMITED ALMAC SCIENCES (SCOTLAND) LIMITED ALMAC SCIENCES LIMITED APTUIT (OXFORD) LIMITED APTUIT (OXFORD) LIMITED ARC TRINOVA LIMITED BASILDON CHEMICAL COMPANY LIMITED BAXTER HEALTHCARE LIMITED BAXTER HEALTHCARE LIMITED BIO PRODUCTS LABORATORY LIMITED BSPG LABORATORIES LIMITED CATALENT MICRON TECHNOLOGIES LIMITED COURTIN & WARNER LIMITED CRODA EUROPE LIMITED CRODA EUROPE LIMITED DR REDDY'S LABORATORIES (EU) LIMITED DSM NUTRITIONAL PRODUCTS (UK) LIMITED EUROAPI UK LIMITED
    [Show full text]
  • British Thoracic Society Winter Meeting
    February 2021 Volume 76 Supplement 1 76 S1 Volume 76 Supplement 1 Pages A1–A256 ThoraxAN INTERNATIONAL JOURNAL OF RESPIRATORY MEDICINE British Thoracic Society THORAX Winter Meeting Wednesday 17 to Friday 19 February 2021 Programme and Abstracts February 2021 February thorax.bmj.com PROGRAMME AND Thorax ABSTRACTS British Thoracic Society Winter Meeting Wednesday 17 to Friday 19 February 2021 Programme and Abstracts Approved by the Federation of the Royal Colleges of Physicians of the UK for 18 category I (external) credits (6 credits per day). Code: 133787 DAILY PROGRAMME WEDNESDAY 17 FEBRUARY 2021 All Symposia, Guest Lectures, Journal Clubs and Spoken Sessions will be shown online live at the times below, and will be available to view via the relevant ‘session type’ tab online. Poster presentations will be pre-recorded and available on demand each day and should be viewed prior to the Poster Discussion Q&A, which will be online live at the times below, all via the ‘Poster Sessions’ tab. Time Session Type Session Title 7.00am – 6.00pm Poster viewing on demand P1-P11 Lessons from COVID-19 throughout the day with live P12-P24 Lung cancer: treatment options and care pathways discussions at the programmed P38-P51 COPD: clinical science times P63-P75 Primary care and paediatric asthma P76-P88 Virtually systematic: current interventions and digital delivery in pulmonary rehabilitation 7.45am – 8.00am Symposium Daily preview 8.00am – 8.30am BTS Journal Club New insights to chronic cough 8.30am – 10.00am Symposium Neutrophilic asthma 8.30am –
    [Show full text]
  • Lopinavir; Ritonavir (All Populations Monograph)
    3/17/2020 Clinical Pharmacology powered by ClinicalKey Lopinavir; Ritonavir (All Populations Monograph) Indications/Dosage expand all | collapse all Labeled human immunodeficiency virus (HIV) infection Off-Label, Recommended coronavirus disease 2019 (COVID-19) † severe acute respiratory syndrome coronavirus 2 (SARS- human immunodeficiency virus (HIV) prophylaxis † CoV-2) infection † † Off-label indication NOTE: HIV guidelines recommend consideration be given to avoiding use of lopinavir; ritonavir-containing regimens in patients at high risk for cardiovascular adverse events.[46638] Initiation of therapy for HIV treatment: [46638] [23512] [42452] For adults, initiation of treatment immediately (or as soon as possible) after HIV diagnosis is recommended in all patients to reduce the risk of disease progression and to prevent the transmission of HIV, including perinatal transmission and transmission to sexual partners. Starting antiretroviral therapy early is particularly important for patients with AIDS-defining conditions, those with acute or recent HIV infection, and individuals who are pregnant; delaying therapy in these subpopulations has been associated with high risks of morbidity, mortality, and HIV transmission. Antiretroviral drug-resistance testing: Genotypic drug-resistance testing is recommended prior to initiation of therapy in all antiretroviral treatment- naive patients and prior to changing therapy for treatment failure. Phenotypic resistance testing may be used in conjunction with the genotypic test for patients with known or suspected complex drug-resistance mutation patterns. HIV-1 proviral DNA resistance testing is available for use in patients with HIV RNA concentrations below the limits of detection or with low-level viremia (i.e., less than 1,000 copies/mL), where genotypic testing is unlikely to be successful; however, the clinical utility of this assay has not been fully determined.
    [Show full text]
  • The World's Health Care Crisis
    The World’s Health Care Crisis This page intentionally left blank The World’s Health Care Crisis From the Laboratory Bench to the Patient’s Bedside By Ibis Sánchez-Serrano AMSTERDAM • BOSTON • HEIDELBERG • LONDON • NEW YORK • OXFORD PARIS • SAN DIEGO • SAN FRANCISCO • SINGAPORE • SYDNEY • TOKYO Elsevier 32 Jamestown Road, London, NW1 7BY 225 Wyman Street, Waltham, MA 02451, USA First edition 2011 Copyright © 2011 Elsevier Inc. All rights reserved No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the Publisher. Details on how to seek permission, further information about the Publisher’s permissions policies and our arrangement with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency, can be found at our website: www.elsevier.com/permissions This book and the individual contributions contained in it are protected under copyright by the Publisher (other than as may be noted herein). Notices Knowledge and best practice in this field are changing constantly. As new research and experience broaden our understanding, changes in research methods, professional practices, or medical treatment may become necessary. Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds, or experiments described herein. In using such information or methods, they should be mindful of their own safety and the safety of others, including parties for whom they have a professional responsibility. To the fullest extent of the law, neither the Publisher nor the authors, contributors, or editors, assume any liability for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein.
    [Show full text]
  • Gertrude B. Elion 1918 Cobb Street #2301 [email protected] New York, NY 10009 (555) 555-6789 Match Number 02211999
    Gertrude B. Elion 1918 Cobb Street #2301 [email protected] New York, NY 10009 (555) 555-6789 Match Number 02211999 EDUCATION Doctor of Pharmacy September 0000- June 0000 Brooklyn Polytechnic Institute New York, NY Bachelor of Science in Biology December 0000-March 0000 Hunter College New York, NY COMPLETED CLERKSHIP ROTATIONS Fairway Market: Kips Bay December 0000 Preceptor: Bertha Cohen, PharmD New York, NY Outpatient community pharmacy experience primarily serving a diverse adult population Provided counseling for patients receiving new medications and gave recommendations for over the counter products Recommended and administered vaccinations Communicated with pharmacies and clinics to receive verbal orders and prescription transfers New York City Pharmacy November 0000 Preceptor: George H. Hitchings, PharmD, James Buchanan, PharmD New York, NY Outpatient experience in both a retail pharmacy and a primary care clinic serving community members Provided counseling for patients receiving new medications and Suboxone Developed vaccine, anticoagulation, and weight management recommendations for patients seen at the travel clinic and at the health clinic Performed medication reconciliation and assisted pharmacists with refill authorizations at the primary care clinic Provided diabetes education and lifestyle counseling to those attending the Men’s Health Fair Wrote a literature evaluation on new medications for schizophrenia, bipolar disorder, and major depressive disorder Coler-Goldwater Specialty Hospital October 0000 Preceptor:
    [Show full text]
  • Glaxosmithkline ITA – Wikipedia
    GlaxoSmithKline - Wikipedia https://it.wikipedia.org/wiki/GlaxoSmithKline GlaxoSmithKline Da Wikipedia, l'enciclopedia libera. GlaxoSmithKline plc (Borsa di Londra: GSK (https://it.finance.yahoo.com/q?s=GSK.L), NYSE: GSK GlaxoSmithKline plc (https://www.nyse.com/quote/XNYS:GSK)) è una società britannica operante nel settore farmaceutico, biologico, e sanitario. GlaxoSmithKline è una società di ricerca con un vasto Stato Regno Unito portafoglio di prodotti farmaceutici che comprendono Forma Società per azioni antinfettivi del sistema nervoso centrale (SNC), societaria respiratorio, gastrointestinale/metabolico, oncologico e vaccini. Inoltre ha molti prodotti per l'igiene del Borse Borsa di Londra: GSK consumatore tra cui prodotti per l'igiene orale, bevande valori (https://it.finance.yahoo.com nutrizionali e medicinali da banco. È presente in 37 /q?s=GSK.L) nazioni ed in Italia possiede una sede a San Polo di NYSE: GSK Torrile, vicino a Parma. A Verona la Glaxo nasce il 30 (https://www.nyse.com marzo 1932 con il nome di Società anonima italiana /quote/XNYS:GSK) Nathan Bompiani, antesignana dell'odierna GlaxoSmithKline; dall'anno 2010 il centro ricerche di ISIN GB0009252882 Verona è condiviso con Aptuit[1]. L'Italia è stato il primo (http://www.isin.org/isin- insediamento estero dell'azienda che presto prenderà il preview nome Glaxo, dal greco "Galaktos", a simboleggiare uno /?isin=GB0009252882) dei suoi primi prodotti: il latte in polvere. Fondazione 2000 dalla fusione tra Glaxo Wellcome e SmithKline Beecham Indice Sede Londra principale
    [Show full text]
  • The British Pharmaceutical Industry Since 1851
    The British Pharmaceutical Industry Since 1851 T.A.B. Corley Centre for International Business History, University of Reading Britain’s pharmaceutical industry, like its petroleum industry, is one which possesses a national comparative advantage both technologically and in the balance of overseas trade; yet it is not easy to delineate. Until quite recently, some member companies also made ranges of different products such as foodstuffs, household goods and heavy chemicals. Moreover, many producers in the UK are subsidiaries of overseas pharmaceutical corporations. Even so, the companies involved do form a recognisable industry, competing among themselves in the field of high-technology health care. The outlines of such an industry began to emerge in the 1930s but became far more distinct after 1948 when the National Health Service (NHS) was set up. Official policies of actively encouraging the technological leaders – foreign as well as British – at the expense of the less adventurous followers, through its pricing and clinical testing rules for prescription drugs, allowed those comparative advantages to be built up. Vigorous competition flourishes also in marketing and in distribution to retail chemists and to other outlets for both ethical drugs and ‘over the counter’ remedies. This article outlines some of the principal changes that have taken place from 1851 onwards in the systems of manufacture and distribution of these medicines. It also addresses the question of how and why the transformation occurred from low- to high- 1 technology production, from small to large scale, and from dependence on imports of advanced drugs to a high degree of self-sufficiency at home.
    [Show full text]
  • Expressions 2014
    “We carve stones, we just don’t polish them. We make monuments out of them.” Prof. Dr. Suresh Nagpal Founder Chairman - Krupanidhi Educational Trust Perfect Pharmacist Perfection is a state of being complete, impeccable and being at pinnacle of our chosen profession. We at KCP are passionate about creating Perfect Pharmacists to serve humanity. It takes a lot to be perfect - unceasing practise, mastery, elan, zeitgeist and ethics. KCP is committed to carve and to deliver the Gen Z pharmacists who will embody all these virtues and retain their relentless pursuit for perfection across the pharmaceutical spectrum. Expressions 2014 - Krupanidhi College of Pharmacy | 1 Table of Contents 03 Commendations 33 Team KCP 37 Life@KCP 41 Cognise 99 Happenings@KCP 115 Outside KCP 121 Creative Canvas 2 | Expressions 2014 - Krupanidhi College of Pharmacy Commendations Expressions 2014 - Krupanidhi College of Pharmacy | 3 Message Shri H. R. Bhardwaj His Excellency Governor of Karnataka 22. 05. 2014 I am happy to learn that ‘KRUPANIDHI COLLEGE OF PHARMACY’ Bengaluru, a constituent of “KRUPANIDHI GROUP OF INSTITUTIONS”, established in 1985 has been imparting quality Education in Pharmacy and providing opportunity to the students to groom to excel, is bringing out its College Magazine ‘EXPRESSIONS-2014’ in June 2014 showcasing the academic and cultural talents of the Students, Faculty and Staff. I send my felicitations & best wishes to the Management, Teaching and Non-Teaching Staff, Editorial Team and also the Students of the College on this happy Occasion. SHRI H. R. BHARDWAJ Governor of Karnataka 4 | Expressions 2014 - Krupanidhi College of Pharmacy Message Shri U. T.
    [Show full text]